- Home
- AFCG vs IPHA Comparison
AFCG vs IPHA Comparison
Compare AFCG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFCG
- IPHA
- Stock Information
- Founded
- AFCG 2020
- IPHA 1999
- Country
- AFCG United States
- IPHA France
- Employees
- AFCG N/A
- IPHA N/A
- Industry
- AFCG Real Estate Investment Trusts
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- AFCG Real Estate
- IPHA Health Care
- Exchange
- AFCG Nasdaq
- IPHA Nasdaq
- Market Cap
- AFCG 189.9M
- IPHA 160.1M
- IPO Year
- AFCG 2021
- IPHA 2019
- Fundamental
- Price
- AFCG $6.76
- IPHA $2.00
- Analyst Decision
- AFCG Buy
- IPHA Strong Buy
- Analyst Count
- AFCG 6
- IPHA 1
- Target Price
- AFCG $12.00
- IPHA $11.50
- AVG Volume (30 Days)
- AFCG 228.4K
- IPHA 657.4K
- Earning Date
- AFCG 03-13-2025
- IPHA 03-27-2025
- Dividend Yield
- AFCG 23.35%
- IPHA N/A
- EPS Growth
- AFCG N/A
- IPHA N/A
- EPS
- AFCG 0.78
- IPHA N/A
- Revenue
- AFCG $41,494,025.00
- IPHA $36,202,722.00
- Revenue This Year
- AFCG N/A
- IPHA N/A
- Revenue Next Year
- AFCG N/A
- IPHA $93.37
- P/E Ratio
- AFCG $8.63
- IPHA N/A
- Revenue Growth
- AFCG N/A
- IPHA N/A
- 52 Week Low
- AFCG $6.52
- IPHA $1.29
- 52 Week High
- AFCG $10.88
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- AFCG 22.65
- IPHA 47.22
- Support Level
- AFCG $8.33
- IPHA $1.99
- Resistance Level
- AFCG $8.55
- IPHA $2.15
- Average True Range (ATR)
- AFCG 0.32
- IPHA 0.13
- MACD
- AFCG -0.10
- IPHA -0.03
- Stochastic Oscillator
- AFCG 11.85
- IPHA 3.53
About AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to state-law-compliant cannabis operators in the U.S. Through the management team's deep network and significant credit and cannabis expertise, AFC originates, structures and underwrites loans ranging from $10 million to over $100 million, typically secured by quality real estate assets, license value and cash flows.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.